PUK4 COST UTILITY ANALYSIS OF END-STAGE RENAL DISEASE TREATMENT CHOICES (ETC) MODEL FOR CHRONIC MAINTENANCE DIALYSIS IN THE UNITED STATES.

End-stage renal disease (ESRD) remains a substantial cost burden that currently affects less than 1% of US adults, while steadily accounting for approximately 7% of overall Medicare fee-for-service spending over the past 15 years. Costs were estimated from the societal and healthcare perspective for the 2018 US Medicare population in 1-year cycles over a lifetime time horizon with a 3% discount rate for all health outcome and cost inputs. From the healthcare system perspective, the ICER was $67,528/QALY from the healthcare perspective, which was most sensitive to annual home dialysis costs and patient utility. [Extracted from the article]